Message from Global Head of Human Resources

Corporate Officer,
Head of Human Resources Division
Tomo Yashiki
We welcome you on the journey toward our new long-term Santen 2030 World Vision: "Happiness with Vision." Our aspiration is crystal clear, and we envision that by 2030, Santen will be dynamically transformed from a traditional pharmaceutical company into a Social Innovator to solve eye-related social issues around the world.
Our new chapter of exciting challenges has already begun for future decades. Santen will evolve to better contribute to the eye health of people around the world, but our CORE PRINCIPLE of "Tenki ni sanyo suru," will never change.

The world today is facing an increase in the number and diversification of eye-related issues and needs. For example, there is an estimated 36 million visually-impaired people worldwide, and this number is expected to triple unless appropriate medical solutions are provided.*1 The global increase in myopia patients has become a serious social issue. It is estimated that as a result of economic growth and lifestyle changes, the number of myopia sufferers, including young people, will reach around five billion by 2050.*2 There are also various unmet medical needs around the world, including a lack of established treatments for diseases as well as limitations to patient accessibility to receive available treatments. Additionally, approximately 1.9 million people*3 worldwide suffer from retinitis pigmentosa. This disease develops in teen years and often leads to blindness at an older age. Patients and their family need breakthrough treatment options for their quality of life. It is said that 50% of vision impairment around the world has not been identified or is yet to be addressed.*4

On top of the current variety of eye drops in our lineup, we need to develop more innovative solutions with novel science and technologies, including cell therapy, gene therapy, medical devices, and digital tools. These are just a few areas that Santen is addressing.

Our vision is to create a society that can provide the Happiest Life for every individual, through the Best Vision Experience. With genuine pride of focusing on ophthalmology, Santen's commitment is to build an inclusive society for people around the world, regardless of visual impairment, and we mean it. To best respond to various eye-related global issues, we will actively promote collaboration with external partners as well as open innovation without settling for the status-quo and conventional business frameworks. We will take advantage of our experience and track record in ophthalmology to orchestrate and mobilize key technologies and players around the world.

We also aspire that by 2030 Santen will achieve remarkable growth on a global scale, and be recognized as a truly global company originally founded in Japan. Our Japan business holds a leadership position and continues to be No.1 in this critical market for a wide range of ophthalmic diseases. The sky is the limit for our rapid growth potential in China and other Asian countries against the backdrop of economic growth, population increase, and improved access to the quality of medical care. Our European business continues to play a critical role with a strong global presence, and they are growing even further in emerging markets such as in the Middle East and Africa. It is imperative to build a solid business foundation and be successful in North America, the global hub of innovation.

At Santen, about 4,000 team members around the world are united together under the common goal to solve eye health-related issues, regardless of their nationality, gender, work location and job functions. We currently operate in more than 60 countries around the world and I assure you that there are plenty of meaningful challenges that Santen can provide on your career path. I look forward to meeting with those of you who share Santen's future vision and aspire to become a Social Innovator.

*1
Rupert R A Bourne (2017), Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis, [The LANCET Global Health], September
*2
WHO World Report on Vision
*3
Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006; 1:40.
*4
WHO World Report on Vision
Corporate Officer,
Head of Human Resources Division
Tomo Yashiki

Employment Opportunities at Santen Group

Seeking job opportunities at Santen Group Companies